About shattuck labs inc - STTK
Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.
STTK At a Glance
Shattuck Labs, Inc.
500 West 5th Street
Austin, Texas 78701
| Phone | 1-512-900-4690 | Revenue | 1.00M | |
| Industry | Biotechnology | Net Income | -48,809,000.00 | |
| Sector | Health Technology | Employees | 40 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
STTK Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 253.985 |
| Price to Book Ratio | 2.803 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.728 |
| Enterprise Value to Sales | 178.341 |
| Total Debt to Enterprise Value | 0.014 |
STTK Efficiency
| Revenue/Employee | 25,000.00 |
| Income Per Employee | -1,220,225.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.011 |
STTK Liquidity
| Current Ratio | 11.695 |
| Quick Ratio | 11.695 |
| Cash Ratio | 11.07 |
STTK Profitability
| Gross Margin | -268.80 |
| Operating Margin | -5,153.20 |
| Pretax Margin | -4,880.90 |
| Net Margin | -4,880.90 |
| Return on Assets | -53.264 |
| Return on Equity | -60.252 |
| Return on Total Capital | -57.55 |
| Return on Invested Capital | -58.768 |
STTK Capital Structure
| Total Debt to Total Equity | 2.938 |
| Total Debt to Total Capital | 2.855 |
| Total Debt to Total Assets | 2.66 |
| Long-Term Debt to Equity | 1.923 |
| Long-Term Debt to Total Capital | 1.868 |